MREO
What one share of Mereo Biopharma Group holds
Pharmaceutical Preparations
We are a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. We have developed a portfolio of late-stage clinical product candidates. Our late-stage rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (“OI”) and alvelestat for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (“AATD-LD”).
Mereo Biopharma Group’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.04 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.03 |
| Cash and investments | $0.04 |
| Book value | $0.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $0.00 | −$0.07 | $0.00 | −$0.08 | — | $0.08 |
| 2023 | $0.02 | −$0.04 | $0.00 | −$0.03 | — | $0.07 |
| 2024 | $0.00 | −$0.06 | $0.00 | −$0.04 | — | $0.08 |
| 2025 | $0.00 | −$0.05 | $0.00 | −$0.04 | — | $0.05 |